We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Evolent Health Hits New 52 Week High, Valence Buy the Key
Read MoreHide Full Article
Shares of Evolent Health Inc. (EVH - Free Report) scaled a new 52-week high of $23.64 on Jul 14, eventually closing a tad bit lower at $23.46. This translates into an impressive year-to-date return of roughly 93.7%, significantly higher than the S&P 500 return of 2.27%.
This rally was primarily driven by Evolent’s growing customer base and expanding footprint. The company’s recently announced acquisition of Chicago-based Valence Health is expected to drive growth in the long haul.
This Zacks Rank #3 (Hold) stock has a market cap of around $951.44 million while average volume of shares traded over the last three months is roughly 198.9K.
Key Growth Factors
As of Mar 31, 2016, Evolent had more than $1.2 million lives on its platform. In the first quarter alone, the company added over 50,000 lives in two markets through the expansion into the Medicare Shared Savings Program and an additional 417,000 lives in Medicaid.
The acquisition of Valence will further expand its clientele. Valence serves the likes of The University of Chicago, Cincinnati Children’s, NorthShore and many others. The deal will provide considerable scale to Evolent’s business, as the combined entity will serve 23 long-term operating partners and more than 1.8 million lives in 30 plus states.
Apart from financial benefits, the acquisition strengthens Evolent’s inherent capabilities and expands its growth prospect. Management noted that Valence’s expertise in Medicaid and pediatric value-based care administration will fill-up important gaps in Evolent’s business model.
Evolent also noted that almost 90 contracts are in strategic or initial phases that can be long term opportunities for the company. Per management, the deal will help Evolent to address the needs of the fast growing value-based care market, which is projected to grow more than $45 billion by 2020.
Zacks Rank & Key Picks
Evolent Health has a Zacks Rank #3 (Hold).
Better-ranked stocks include Foundation Medicine , Omnicell (OMCL - Free Report) and Streamline Health (STRM - Free Report) . While Foundation Medicine and Omnicell sport a Zacks Rank #1 (Strong Buy), Streamline carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Evolent Health Hits New 52 Week High, Valence Buy the Key
Shares of Evolent Health Inc. (EVH - Free Report) scaled a new 52-week high of $23.64 on Jul 14, eventually closing a tad bit lower at $23.46. This translates into an impressive year-to-date return of roughly 93.7%, significantly higher than the S&P 500 return of 2.27%.
This rally was primarily driven by Evolent’s growing customer base and expanding footprint. The company’s recently announced acquisition of Chicago-based Valence Health is expected to drive growth in the long haul.
This Zacks Rank #3 (Hold) stock has a market cap of around $951.44 million while average volume of shares traded over the last three months is roughly 198.9K.
Key Growth Factors
As of Mar 31, 2016, Evolent had more than $1.2 million lives on its platform. In the first quarter alone, the company added over 50,000 lives in two markets through the expansion into the Medicare Shared Savings Program and an additional 417,000 lives in Medicaid.
EVOLENT HEALTH Price and Consensus
EVOLENT HEALTH Price and Consensus | EVOLENT HEALTH Quote
The acquisition of Valence will further expand its clientele. Valence serves the likes of The University of Chicago, Cincinnati Children’s, NorthShore and many others. The deal will provide considerable scale to Evolent’s business, as the combined entity will serve 23 long-term operating partners and more than 1.8 million lives in 30 plus states.
Apart from financial benefits, the acquisition strengthens Evolent’s inherent capabilities and expands its growth prospect. Management noted that Valence’s expertise in Medicaid and pediatric value-based care administration will fill-up important gaps in Evolent’s business model.
Evolent also noted that almost 90 contracts are in strategic or initial phases that can be long term opportunities for the company. Per management, the deal will help Evolent to address the needs of the fast growing value-based care market, which is projected to grow more than $45 billion by 2020.
Zacks Rank & Key Picks
Evolent Health has a Zacks Rank #3 (Hold).
Better-ranked stocks include Foundation Medicine , Omnicell (OMCL - Free Report) and Streamline Health (STRM - Free Report) . While Foundation Medicine and Omnicell sport a Zacks Rank #1 (Strong Buy), Streamline carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>